STOCK TITAN

Supernus Pharmaceuticals, Inc. - SUPN STOCK NEWS

Welcome to our dedicated page for Supernus Pharmaceuticals news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharmaceuticals stock.

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is a leading specialty pharmaceutical company dedicated to developing and commercializing innovative products for the treatment of central nervous system (CNS) disorders. With over two decades of experience in the industry, Supernus has made significant strides in neurology and psychiatry.

Supernus’ product portfolio is diverse, including approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. Flagship products include Trokendi XR®, Oxtellar XR®, Qelbree®, APOKYN®, XADAGO®, MYOBLOC®, GOCOVRI®, and Osmolex ER®.

In 2013, Supernus successfully launched two groundbreaking products: Oxtellar XR® and Trokendi XR®, both aimed at treating epilepsy. These innovative formulations offer extended-release solutions, enhancing patient convenience and compliance.

Beyond these milestones, Supernus is actively developing new therapeutic candidates in psychiatry to address unmet medical needs in ADHD, depression, and their co-existing disorders. The company leverages proprietary and in-licensed technologies to create differentiated products. By focusing on known drug compounds with established mechanisms of action, Supernus minimizes the risks, costs, and time associated with new drug development.

Supernus has recently announced notable developments:

  • Financial and business results for Q4 and the full year of 2023 will be reported on February 27, 2024.
  • Actress Busy Philipps has partnered with Supernus to raise awareness about ADHD during Mental Health Awareness Month, spotlighting Qelbree® as a non-stimulant medication for ADHD.
  • Supernus signed an exclusive licensing agreement with M8 Pharmaceuticals to commercialize Qelbree® in Latin America, expanding its reach and impact.

With a strong foundation and ongoing projects, Supernus Pharmaceuticals continues to make significant contributions to the field of CNS disorders, enhancing patient lives through innovative solutions.

Rhea-AI Summary

Supernus Pharmaceuticals (Nasdaq: SUPN) announced that its CEO, Jack Khattar, will present a company overview and update at two upcoming November conferences. The Stifel 2022 Healthcare Conference is scheduled for November 15, 2022, at 8:00 a.m. ET in New York. The 13th Annual Jefferies London Healthcare Conference will take place on November 17, 2022, at 9:05 a.m. ET / 2:05 p.m. GMT in London. Interested investors can arrange meetings through conference coordinators and access live webcasts on the Company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
conferences
-
Rhea-AI Summary

Supernus Pharmaceuticals reported total revenues of $177.4 million for Q3 2022, a 19% increase year-over-year. The company raised its full-year guidance for operating earnings to $35 million to $45 million and total revenues to $650 million to $680 million. Qelbree prescriptions rose to 94,328, a 50% increase from Q2 2022, with net product sales of $18.3 million. GOCOVRI's sales reached $27.9 million, up 16% from the previous year. Adjusted operating earnings for Q3 were $25.4 million, down from $43.3 million in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
-
Rhea-AI Summary

Supernus Pharmaceuticals (Nasdaq: SUPN) announced its upcoming third quarter 2022 financial results, set to be reported after market close on November 8, 2022. CEO Jack Khattar and CFO Tim Dec will host a conference call to discuss the results at 4:30 p.m. ET on the same day.

The call will be available via live webcast on the company's Investor Relations website, where a replay will also be accessible for 60 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
Rhea-AI Summary

Supernus Pharmaceuticals (Nasdaq: SUPN) announced that the FDA issued a Complete Response Letter (CRL) for its SPN-830 New Drug Application (NDA). This investigational apomorphine infusion device targets motor fluctuations in Parkinson's disease. The CRL requests further information about labeling, product quality, and device performance. Notably, the FDA's initial findings do not ask for additional efficacy and safety studies. Supernus aims to address the FDA's concerns and expedite the NDA resubmission, which will undergo a six-month review timeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.66%
Tags
none
-
Rhea-AI Summary

Supernus Pharmaceuticals (Nasdaq: SUPN) announced that President and CEO Jack Khattar will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 8:35 a.m. ET. The conference runs from September 7-9, 2022, at Encore Boston Harbor, Massachusetts. Investors can access a live audio webcast of the presentation via the Company’s website, with an archived replay available for 60 days. Supernus focuses on developing treatments for central nervous system diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
conferences
-
Rhea-AI Summary

Supernus Pharmaceuticals reported Q2 2022 revenues of $170.1 million, reflecting a 20% increase year-over-year. The company's GAAP operating earnings stood at $11.3 million, down from $34.1 million in Q2 2021. Notably, Qelbree prescriptions surged to 62,938, marking a 33% increase from Q1 2022. Net product sales for Qelbree grew by 34% quarter-over-quarter, reaching $11.1 million. The company maintains a robust cash position of $508.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
Rhea-AI Summary

Supernus Pharmaceuticals (Nasdaq: SUPN) has announced the upcoming release of its financial and business results for Q2 2022 on August 4, 2022, after market close. The conference call, hosted by President and CEO Jack Khattar and CFO Tim Dec, will begin at 4:30 p.m. ET. Investors can pre-register for the call and access a live webcast through the company's Investor Relations website. Supernus is focused on CNS disease treatments and is advancing a range of product candidates for various neurological disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
-
Rhea-AI Summary

Supernus Pharmaceuticals (Nasdaq: SUPN) will present at the Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET. CEO Jack Khattar will lead the presentation, highlighting the company’s focus on CNS diseases.

Investors can arrange meetings through the conference coordinator. The event occurs from June 8-10, 2022, at the New York Marriott Marquis. A live audio webcast will be available on the company's website, with a replay for 60 days post-conference. Supernus is known for its CNS product portfolio, including treatments for epilepsy, migraines, and Parkinson’s disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
conferences
-
Rhea-AI Summary

Supernus Pharmaceuticals reported first quarter 2022 revenues of $152.5 million, a 16% increase year-over-year. Net earnings rose to $25.6 million or $0.43 per diluted share. GAAP operating income stood at $2.0 million, while non-GAAP operating income was $28.0 million, reflecting an 11% increase from 2021. The FDA approved Qelbree® for adult ADHD treatment, contributing to 47,324 prescriptions in Q1, a 38% increase from Q4 2021. Financial guidance for 2022 remains $640 - $680 million in total revenues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
Rhea-AI Summary

Supernus Pharmaceuticals (Nasdaq: SUPN) announced it will report Q1 2022 financial results after the market closes on May 9, 2022. President and CEO Jack Khattar and CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss the results, with a Q&A session following. A live webcast will be available on the Supernus website. The company specializes in developing CNS disease treatments, including products for epilepsy, migraine, and Parkinson’s disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags

FAQ

What is the current stock price of Supernus Pharmaceuticals (SUPN)?

The current stock price of Supernus Pharmaceuticals (SUPN) is $35.43 as of December 20, 2024.

What is the market cap of Supernus Pharmaceuticals (SUPN)?

The market cap of Supernus Pharmaceuticals (SUPN) is approximately 2.0B.

What types of disorders does Supernus Pharmaceuticals focus on?

Supernus Pharmaceuticals focuses on central nervous system (CNS) disorders, including epilepsy, migraine, ADHD, Parkinson's Disease (PD), and various psychiatric conditions.

What are some of the key products developed by Supernus Pharmaceuticals?

Key products include Trokendi XR®, Oxtellar XR®, Qelbree®, APOKYN®, XADAGO®, MYOBLOC®, GOCOVRI®, and Osmolex ER®.

What recent collaborations has Supernus Pharmaceuticals announced?

Supernus has partnered with Busy Philipps to raise ADHD awareness and signed an exclusive licensing agreement with M8 Pharmaceuticals to commercialize Qelbree® in Latin America.

When will Supernus Pharmaceuticals report its financial results for Q4 and the full year of 2023?

Supernus Pharmaceuticals will report its financial results for Q4 and the full year of 2023 on February 27, 2024.

What is the significance of Qelbree®?

Qelbree® is a non-stimulant medication for ADHD, offering a new treatment option for both children and adults. It stands out for its extended-release formulation.

How does Supernus Pharmaceuticals leverage its proprietary technologies?

Supernus utilizes proprietary and in-licensed technologies to develop differentiated products, focusing on known drug compounds to reduce risks, costs, and development time.

What is the main focus of Supernus Pharmaceuticals' ongoing projects?

Current projects focus on developing new treatments for ADHD, depression, and their co-existing disorders, aiming to address unmet medical needs effectively.

Who are the key executives at Supernus Pharmaceuticals?

Key executives include Jack A. Khattar (President and CEO) and Timothy C. Dec (Senior Vice President and CFO).

What are the safety concerns related to Qelbree®?

Qelbree® may increase suicidal thoughts and actions, especially in the first few months. It can also increase blood pressure and heart rate and may cause manic episodes in patients with bipolar disorder.

Where can I find more information about Supernus Pharmaceuticals and its products?

More information is available on the company's official website at www.supernus.com.

Supernus Pharmaceuticals, Inc.

Nasdaq:SUPN

SUPN Rankings

SUPN Stock Data

2.00B
52.45M
5.01%
113.3%
11.81%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
ROCKVILLE